- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Edgewise Therapeutics Inc (EWTX)
Edgewise Therapeutics Inc stock price live, this page displays NASDAQ EWTX stock exchange data. View the EWTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Edgewise Therapeutics Inc real time stock price chart below.
What Is the Edgewise Therapeutics Inc Stock Price Today?
The Edgewise Therapeutics Inc stock price today is 45.32.
What Is the Stock Symbol for Edgewise Therapeutics Inc?
The stock symbol for Edgewise Therapeutics Inc is "EWTX."
What Stock Exchange Does Edgewise Therapeutics Inc Trade On?
Edgewise Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Edgewise Therapeutics Inc a Good Stock to Buy?
Determining whether Edgewise Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EWTX quote. (ISIN: US28036F1057)
What Is the Edgewise Therapeutics Inc Stock Price Today?
The Edgewise Therapeutics Inc stock price today is 45.32.
What Is the Stock Symbol for Edgewise Therapeutics Inc?
The stock symbol for Edgewise Therapeutics Inc is "EWTX."
What Stock Exchange Does Edgewise Therapeutics Inc Trade On?
Edgewise Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Edgewise Therapeutics Inc a Good Stock to Buy?
Determining whether Edgewise Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EWTX quote. (ISIN: US28036F1057)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
45.32
46.93
52 wk Range
14.25
48.51
EWTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
45.3246.93
52 wk Range
14.2548.51
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EWTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
51.69
Upside
+14.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Analyst Ratings
11 Buy
2 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 51.69
(+14.06% Upside)
Edgewise Therapeutics Inc SWOT Analysis
Novel Therapies | Edgewise Therapeutics develops innovative treatments for rare muscle disorders, with lead candidate EDG-7500 in clinical trials for hypertrophic cardiomyopathy |
Clinical Milestones | Explore the company's catalyst-rich 2025, featuring crucial data readouts for EDG-7500 and sevasemten in muscular dystrophy programs |
Market Potential | Delve into Edgewise's positioning in the lucrative rare disease market, addressing significant unmet needs in HCM and muscular dystrophy |
Analyst Outlook | Learn about the bullish sentiment surrounding EWTX, with price targets ranging from $30 to $56, reflecting substantial upside potential |
Earnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.53 / -0.47
Revenue / Forecast
-- / --
Compare EWTX to Peers and Sector
Metrics to compare | EWTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEWTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −25.0x | −0.5x | −0.4x | |
PEG Ratio | 1.29 | −0.33 | 0.00 | |
Price/Book | 11.0x | −16.8x | 2.6x | |
Price / LTM Sales | - | 2.1x | 3.0x | |
Upside (Analyst Target) | 14.1% | 51.8% | 54.5% | |
Fair Value Upside | Unlock | 14.0% | 7.2% | Unlock |
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Edgewise Therapeutics (EWTX) Stock Price Today?
The Edgewise Therapeutics stock price today is 45.32 USD.
What Stock Exchange Does Edgewise Therapeutics Trade On?
Edgewise Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Edgewise Therapeutics?
The stock symbol for Edgewise Therapeutics is "EWTX."
What Is the Edgewise Therapeutics Market Cap?
As of today, Edgewise Therapeutics market cap is 4.92B USD.
What Is Edgewise Therapeutics's Earnings Per Share (TTM)?
The Edgewise Therapeutics EPS (TTM) is -1.85.
When Is the Next Edgewise Therapeutics Earnings Date?
Edgewise Therapeutics will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is EWTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Edgewise Therapeutics Stock Split?
Edgewise Therapeutics has split 0 times.
How Many Employees Does Edgewise Therapeutics Have?
Edgewise Therapeutics has 127 employees.
What is the current trading status of Edgewise Therapeutics (EWTX)?
As of Sep 20, 2026, Edgewise Therapeutics (EWTX) is trading at a price of 45.32 USD, with a previous close of 45.32 USD. The stock has fluctuated within a day range of 45.32 USD to 46.93 USD, while its 52-week range spans from 14.25 USD to 48.51 USD.
What Is Edgewise Therapeutics (EWTX) Price Target According to Analysts?
The average 12-month price target for Edgewise Therapeutics is 51.69 USD, with a high estimate of 66 USD and a low estimate of 36 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +14.06% Upside potential.
What Is the EWTX Premarket Price?
EWTX's last pre-market stock price is 46.50 USD. The pre-market share volume is 20,330.00, and the stock has decreased by -0.44, or -0.94%.
What Is the EWTX After Hours Price?
EWTX's last after hours stock price is 44.42 USD, the stock has decreased by -0.90, or -1.99%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.